Design and NMR characterization of active analogues of compstatin containing non-natural amino acids

Journal of Medicinal Chemistry

Volumn 48, Issue 1, 2005, Pages 274-286

  Mallik, Buddhadeb ^a   Katragadda, Madan ^a   Spruce, Lynn A ^b   Carafides, Caterina ^b   Tsokos, Christos G ^b   Morikis, Dimitrios ^a   Lambris, John D ^b  

^a University of California Riverside   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALANINE; AMINO ACID DERIVATIVE; COMPSTATIN DERIVATIVE; DISULFIDE; PEPTIDE; TRYPTOPHAN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; DRUG ACTIVITY; DRUG ANALYSIS; DRUG BINDING; DRUG DESIGN; DRUG INHIBITION; HYDROPHOBICITY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE; NUCLEAR OVERHAUSER EFFECT; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

AMINO ACIDS; BINDING SITES; CELLS, CULTURED; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PEPTIDES, CYCLIC; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 12144250759     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0495531     Document Type: Article

References (52)

1. Lambris, J. D.; Reid, K. B. M.; Volanakis, J. E. The evolution, structure, biology and pathophysiology of complement. Immunol. Today 1999, 20, 207-211.
2. Walport, M. J. Complement. Second of two parts. New Engl. J. Med. 2001, 344, 1140-1144.
3. Walport, M. J. Complement. First of two parts. New Engl. J. Med. 2001, 344, 1058-1066.
4. Morikis, D.; Soulika, A. M.; Mallik, B.; Klepeis, J. L.; Floudas, C. A. et al. Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. Biochem. Soc. Trans. 2004, 32, 28-32.
5. Morikis, D.; Lambris, J. D. Structural aspects and design of low-molecular-mass complement inhibitors. Biochem. Soc. Trans. 2002, 30, 1026-1036.
6. Sahu, A.; Morikis, D.; Lambris, J. D. Complement inhibitors targeting C3, C4, and C5. Therapeutic interventions in the complement system; Lambris, J. D., Holers, V. M., (Eds.); Humana Press: Totowa, NJ, 2000; pp 75-112.
7. Sahu, A.; Lambris, J. D. Complement inhibitors: A resurgent concept in antiinflammatory therapeutics. Immunopharmacology 2000, 49, 133-148.
8. Morikis, D.; Sahu, A.; Moore, W. T.; Lambris, J. D. Design, structure, function and application of compstatin. Bioactive peptides in drug discovery and design: Medical aspects; Matsoukas, J., Mavromoustakos, T., (Eds.); Ios Press: Amsterdam, 1999; pp 235-246.
9. Sahu, A.; Lambris, J. D. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol. Rev. 2001, 180, 35-48.
10. Lambris, J. D., Holers, V. M. (Eds.) Therapeutic interventions in the complement system; Humana Press: Totowa, NJ, 2000.
11. Morgan, B. P.; Harris, C. L. Complement therapeutics; history and current progress. Mol. Immunol. 2003, 40, 159-170.
12. Makrides, S. C. Therapeutic inhibition of the complement system. Pharmacol. Rev. 1998, 50, 59-87.
13. Sahu, A.; Kay, B. K.; Lambris, J. D. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 1996, 157, 884-891.
14. Nilsson, B.; Larsson, R.; Hong, J.; Elgue, G.; Ekdahl, K. N.; et al. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998, 92, 1661-1667.
15. Fiane, A. E.; Mollnes, T. E.; Videm, V.; Hovig, T.; Hogasen, K. et al. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation 1999, 6, 52-65.
16. Fiane, A. E.; Mollnes, T. E.; Videm, V.; Hovig, T.; Hogasen, K. et al. Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor Compstatin. Transplant Proc. 1999, 31, 934-935.
17. Soulika, A. M.; Khan, M. M.; Hattori, T.; Bowen, F. W.; Richardson, B. A. et al. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin. Immunol. 2000, 96, 212-221.
18. Sahu, A.; Soulika, A. M.; Morikis, D.; Spruce, L.; Moore, W. T. et al. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J. Immunol. 2000, 165, 2491-2499.
19. Furlong, S. T.; Dutta, A. S.; Coath, M. M.; Gormley, J. J.; Hubbs, S. J. et al. C3 activation is inhibited by analogues of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles. Immunopharmacology 2000, 48, 199-212.
20. Mollnes, T. E.; Brekke, O. L.; Fung, M.; Fure, H.; Christiansen, D. et al. Essential role of the C5a receptor in E-coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002, 100, 1869-1877.
21. Klegeris, A.; Singh, E. A.; McGeer, P. L. Effects of C-reactive protein and pentosan polysulphate on human complement activation. Immunology 2002, 106, 381-388.
22. Sahu, A.; Morikis, D.; Lambris, J. D. Compstatin, a peptide inhibitor of complement, exhibits species- specific binding to complement component C3. Mol. Immunol. 2003, 39, 557-566.
23. Soulika, A. M.; Morikis, D.; Sarrias, M. R.; Roy, M.; Spruce, L. A.; et al. Studies of structure-activity relations of complement inhibitor compstatin. J. Immunol. 2003, 171, 1881-1890.
24. Schmidt, S.; Haase, G.; Csomor, E.; Lutticken, R.; Peltroche- Llacsahuanga, H. Inhibitor of complement, Compstatin, prevents polymer-mediated Mac-1 up-regulation of human neutrophils independent of biomaterial type tested. J. Biomed. Mater. Res. Part A 2003, 66A, 491-499.
25. Morikis, D.; Assa-Munt, N.; Sahu, A.; Lambris, J. D. Solution structure of compstatin, a potent complement inhibitor. Protein Sci. 1998, 7, 619-627.
26. Klepeis, J. L.; Floudas, C. A.; Morikis, D.; Lambris, J. D. Predicting peptide structures using NMR data and deterministic global optimization. J. Comput. Chem. 1999, 20, 1354-1370.
27. Mallik, B.; Lambris, J. D.; Morikis, D. Conformational interconversion in compstatin probed with molecular dynamics simulations. Proteins-Struct. Funct. Genet. 2003, 53, 130-141.
28. Morikis, D.; Roy, M.; Sahu, A.; Troganis, A.; Jennings, P. A.; et al. The structural basis of compstatin activity examined by structure-function-based design of peptide analogues and NMR. J. Biol. Chem. 2002, 277, 14942-14953.
29. Klepeis, J. L.; Floudas, C. A.; Morikis, D.; Tsokos, C. G.; Argyropoulos, E.; et al. Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. J. Am. Chem. Soc. 2003, 125, 8422-8423.
30. Klepeis, J. L.; Floudas, C. A.; Morikis, D.; Tsokos, C. G.; Lambris, J. D. Design of peptide analogues with improved activity using a novel de novo protein design approach. Ind. Eng. Chem. Res. 2004, 43, 3817-3826.
31. Fields, G. B.; Noble, R. L. Solid-Phase Peptide-Synthesis Utilizing 9-Fluorenylmethoxycarbonyl Amino-Acids. Int. J. Pept. Protein Res. 1990, 35, 161-214.
32. Edwards, W. B.; Fields, C. G.; Anderson, C. J.; Pajeau, T. S.; Welch, M. J. et al. Generally Applicable, Convenient Solid-Phase Synthesis and Receptor Affinities of Octreotide Analogues. J. Med. Chem, 1994, 37, 3749-3757.
33. Hillenkamp, F.; Karas, M. Mass-Spectrometry of Peptides and Proteins by Matrix-Assisted Ultraviolet-Laser Desorption Ionization. Methods Enzymol. 1990, 193, 280-295.
34. Zaluzec, E. J.; Gage, D. A.; Watson, J. T. Matrix-Assisted Laser-Desorption Ionization Mass-Spectrometry-Applications in Peptide and Protein Characterization. Protein Expression Purification 1995, 6, 109-123.
35. Sittampalam, G. S.; Ellis, R. M.; Miner, D. J.; Rickard, E. C.; Clodfelter, D. K. Evaluation of Amino-Acid Analysis as Reference Method to Quantitate Highly Purified Proteins. J. Assoc. Official Anal. Chem. 1988, 71, 833-838.
36. Chang, J. Y. The Functional Domain of Hirudin, a Thrombin-Specific Inhibitor. FEBS Lett. 1983, 164, 307-313.
37. Ernst, R. R.; Bodenhausen, G.; Wokaun, A. Principles of nuclear magnetic resonance spectroscopy in one and two dimensions; Oxford Univeristy Press: Oxford, 1990.
38. Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; et al. NMRPipe - A Multidimensional Spectral Processing System Based on Unix Pipes. J. Biomol. NMR 1995, 6, 277-293.
39. Johnson, B. A.; Blevins, R. A. NMRView - A Computer-Program for the Visualization and Analysis of NMR Data. J. Biomol. NMR 1994, 4, 603-614.
40. 10-helix and alpha-helix in Ala-rich peptides: A hydrogen exchange and high field NMR study. J. Mol. Biol. 1997, 267, 963-974.
41. 10-helix vs alpha-helix formation in peptides: Percentage of C-alpha-tetrasubstituted alpha-amino acid residues and sequence dependence. Biopolymers 2002, 64, 236-245.
42. Wuthrich, K. NMR of proteins and nucleic acids; Wiley-Interscience: New York, 1986.
43. Wishart, D. S.; Sykes, B. D.; Richards, F. M. Relationship between nuclear-magnetic-resonance chemical-shift and protein secondary structure. J. Mol. Biol. 1991, 222, 311-333.
44. Szilagyi, L. Chemical-shifts in proteins come of age. Progress in Nuclear Magn. Reson. Spectrosc. 1995, 27, 325-443.
45. Merutka, G.; Morikis, D.; Bruschweiler, R.; Wright, P. E. NMR evidence for multiple conformations in a highly helical model peptide. Biochemistry 1993, 32, 13089-13097.
46. Burley, S. K.; Petsko, G. A. Aromatic-aromatic interaction - A mechanism of protein-structure stabilization. Science 1985, 229, 23-28.
47. Gervasio, F. L.; Chelli, R.; Procacci, P.; Schettino, V. The nature of intermolecular interactions between aromatic amino acid residues. Proteins-Struct. Funct. Genet. 2002, 48, 117-125.
48. Meyer, E. A.; Castellano, R. K.; Diederich, F. Interactions with aromatic rings in chemical and biological recognition. Angew. Chem. Int. Ed. 2003, 42, 1210-1250.
49. Burley, S. K.; Petsko, G. A. Amino-Aromatic Interactions in Proteins. FEBS Lett. 1988, 203, 139-143.
50. Gallivan, J. P.; Dougherty, D. A. Cation-pi interactions in structural biology. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9459-9464.
51. Zacharias, N.; Dougherty, D. A. Cation-pi interactions in ligand recognition and catalysis. Trends Pharmacol. Sci. 2002, 23, 281-287.
52. 1H Chemical-shifts obtained as a function of temperature and trifluoroethanol concentration for the peptide series GGXGG. J. Biomol. NMR 1995, 5, 14-24.